Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.

Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES.

Prostate. 2012 Apr;72(5):487-98. doi: 10.1002/pros.21449. Epub 2011 Jul 11.

PMID:
21748755
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.

Keizman D, Zahurak M, Sinibaldi V, Carducci M, Denmeade S, Drake C, Pili R, Antonarakis ES, Hudock S, Eisenberger M.

Clin Cancer Res. 2010 Nov 1;16(21):5269-76. doi: 10.1158/1078-0432.CCR-10-1928. Epub 2010 Oct 26.

PMID:
20978144
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Is undetectable prostate-specific antigen always reliable to rule out prostate cancer recurrence after radical prostatectomy?

Schriefer P, Steurer S, Huland H, Graefen M.

J Clin Oncol. 2012 Nov 10;30(32):e341-4. doi: 10.1200/JCO.2012.43.1767. Epub 2012 Oct 1. No abstract available.

PMID:
23032622
[PubMed - indexed for MEDLINE]
4.

Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer.

Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP.

Prostate. 1999 Oct 1;41(2):127-33.

PMID:
10477909
[PubMed - indexed for MEDLINE]
5.

Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy.

Marschner N, Rüttinger D, Zugmaier G, Nemere G, Lehmann J, Obrist P, Baeuerle PA, Wolf A, Schmidt M, Abrahamsson PA, Reinhardt C, Heidenreich A.

Urol Int. 2010;85(4):386-95. doi: 10.1159/000318055. Epub 2010 Jul 2.

PMID:
20606402
[PubMed - indexed for MEDLINE]
6.

False elevations in prostate-specific antigen levels affecting patient management.

Kummar S, Shafi NQ.

Clin Adv Hematol Oncol. 2004 Sep;2(9):599-601; discussion 602. No abstract available.

PMID:
16163243
[PubMed - indexed for MEDLINE]
7.

Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.

Antonarakis ES, Zahurak ML, Lin J, Keizman D, Carducci MA, Eisenberger MA.

Cancer. 2012 Mar 15;118(6):1533-42. doi: 10.1002/cncr.26437.

PMID:
21960118
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer.

Beinart G, Rini BI, Weinberg V, Small EJ.

Clin Prostate Cancer. 2005 Jun;4(1):55-60.

PMID:
15992463
[PubMed - indexed for MEDLINE]
9.

Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.

Cheng L, Jones TD, Lin H, Eble JN, Zeng G, Carr MD, Koch MO.

J Urol. 2005 Dec;174(6):2181-5.

PMID:
16280760
[PubMed - indexed for MEDLINE]
10.

Cytokine variations in patients with hormone treated prostate cancer.

Wise GJ, Marella VK, Talluri G, Shirazian D.

J Urol. 2000 Sep;164(3 Pt 1):722-5.

PMID:
10953133
[PubMed - indexed for MEDLINE]
11.

Mitoxantrone in patients with prostate specific antigen progression after local therapy for prostate carcinoma.

DiPaola RS, Chenven ES, Shih WJ, Lin Y, Amenta P, Goodin S, Shumate A, Capanna T, Cardiella M, Cummings KB, Aisner J, Todd MB.

Cancer. 2001 Oct 15;92(8):2065-71.

PMID:
11596021
[PubMed - indexed for MEDLINE]
12.

MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy.

Silverman JM, Krebs TL.

AJR Am J Roentgenol. 1997 Feb;168(2):379-85.

PMID:
9016212
[PubMed - indexed for MEDLINE]
13.

Thomsen-Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer.

Slovin SF, Ragupathi G, Musselli C, Fernandez C, Diani M, Verbel D, Danishefsky S, Livingston P, Scher HI.

Cancer Immunol Immunother. 2005 Jul;54(7):694-702. Epub 2005 Feb 22.

PMID:
15726361
[PubMed - indexed for MEDLINE]
14.

Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.

Kibel AS, Rosenbaum E, Kattan MW, Picus J, Dreicer R, Klein EA, Chatta GS, Nelson JB, DiPaola RS, Roth BJ, Cookson MS, Wilding G, Jarrard DF, Beer TM, Ryan CW, Petrylak DP, Benson MC, Partin AW, Garrett-Mayer E, Eisenberger MA.

J Urol. 2007 May;177(5):1777-81.

PMID:
17437819
[PubMed - indexed for MEDLINE]
15.

[The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma].

Stamey TA.

Urologe A. 1990 Mar;29(2):52-64. German.

PMID:
1691883
[PubMed - indexed for MEDLINE]
16.

Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.

Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ.

J Urol. 2008 Nov;180(5):2011-7; discussion 2017-8. doi: 10.1016/j.juro.2008.07.048. Epub 2008 Sep 17.

PMID:
18801509
[PubMed - indexed for MEDLINE]
17.

Comparison of the percent free prostate-specific antigen levels in the serum of healthy men and in men with recurrent prostate cancer after radical prostatectomy.

Scorilas A, Yu H, Soosaipillai AR, Gregorakis AK, Diamandis EP.

Clin Chim Acta. 2000 Feb 25;292(1-2):127-38.

PMID:
10686282
[PubMed - indexed for MEDLINE]
18.

Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA.

Barrou B, Benoît G, Ouldkaci M, Cussenot O, Salcedo M, Agrawal S, Massicard S, Bercovici N, Ericson ML, Thiounn N.

Cancer Immunol Immunother. 2004 May;53(5):453-60. Epub 2004 Feb 4.

PMID:
14760510
[PubMed - indexed for MEDLINE]
19.

A model that predicts the probability of positive imaging in prostate cancer cases with biochemical failure after initial definitive local therapy.

Choueiri TK, Dreicer R, Paciorek A, Carroll PR, Konety B.

J Urol. 2008 Mar;179(3):906-10; discussion 910. doi: 10.1016/j.juro.2007.10.059. Epub 2008 Jan 22.

PMID:
18207194
[PubMed - indexed for MEDLINE]
20.

Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial.

Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN Jr, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR.

Clin Genitourin Cancer. 2009 Jan;7(1):43-50. doi: 10.3816/CGC.2009.n.008.

PMID:
19213668
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk